Sarcoidosis induced by interferon-α in melanoma patients: Incidence, clinical manifestations, and management strategies

Journal of Immunotherapy

Volumn 33, Issue 8, 2010, Pages 834-839

  Heinzerling, Lucie M ^a   Anliker, Mark D ^a   Müller, Joachim ^a   Schlaeppi, Marc ^a   Von Moos, Roger ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

TH1 response; drug reaction; granuloma; Morbus Boeck; pegylated interferon

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; STEROID;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HUMAN; INCIDENCE; MALE; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOIDOSIS; URINALYSIS;

DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GRANULOMA; HEPATITIS C; HUMANS; IMMUNOTHERAPY; INCIDENCE; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SARCOIDOSIS; WITHHOLDING TREATMENT;

EID: 77958061094     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181eef779     Document Type: Article

References (38)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
2. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117-126.
3. Eggermont AM SS, Santinami M, Testori A, et al.; EORTC Melanoma Group. Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2644 patients. ASCO. 2009;27:15s.
4. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS executive committee, February; 1999. Am J Respir Crit Care Med.;1999; 160;736-755.
5. Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis statement committee. American thoracic society. European respiratory society. World association for sarcoidosis and other granulomatous disorders. Eur Respir J. 1999;14:735-737.
6. Hunninghake GW, Costabel U, Ando M, et al. ATS/ ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149-173.
7. Newman LS, Rose CS, Maier LA, Sarcoidosis. N Engl J Med; 1997; 336; 1224-1234.
8. Akahoshi M, Ishihara M, Remus N, et al. Association between IFNA genotype and the risk of sarcoidosis. Hum Genet. 2004;114:503-509.
9. Doyle MK, Berggren R, Magnus JH. Interferon-induced sarcoidosis. J Clin Rheumatol. 2006;12:241-248.
10. Hoffmann RM, Jung MC, Motz R, et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol. 1998;28:1058-1063.
11. Hendrickx BW, van Herpen CM, Bonenkamp JJ, et al. Positive positron emission tomography scan in sarcoidosis and two challenging cases of metastatic cancer. CASE 1. Mediastinal sarcoidosis in a melanoma patient treated with interferon. J Clin Oncol. 2005;23:8906-8907.
12. Aoki J, Watanabe H, Shinozaki T, et al. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol. 2003;32:133-138.
13. Goldberg HJ, Fiedler D, Webb A, et al. Sarcoidosis after treatment with interferon-alpha: a case series and review of the literature. Respir Med. 2006;100:2063-2068.
14. Chen YC, Lu SN, Lin MC. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Chang Gung Med J. 2007;30: 92-97.
15. Stern BJ, Aksamit A, Clifford D, et al. Neurologic presentations of sarcoidosis. Neurol Clin. 2010;28:185-198.
16. Miwa H, Furuya T, Tanaka S, et al. Neurosarcoidosis associated with interferon therapy. Eur Neurol. 2001;45: 288-289.
17. Menon Y, Cucurull E, Reisin E, et al. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci. 2004;328:173-175.
18. Toulemonde A, Quereux G, Dreno B. Sarcoidosis granuloma on a tattoo induced by interferon alpha. Ann Dermatol Venereol. 2004;131:49-51.
19. Robert C, Schoenlaub P, Avril MF, et al. Malignant melanoma and granulomatosis. Br J Dermatol. 1997;137: 787-792.
20. Massaguer S, Sanchez M, Castel T. Mediastinal sarcoidosis induced by high-dose alpha-2-interferon therapy in a patient with malignant melanoma. Eur Radiol. 2004;14:1716-1717.
21. Kreutzer K, Bonnekoh B, Franke I, et al. Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma? J Dtsch Dermatol Ges. 2004;2:689-694.
22. Alonso-Perez A, Ballestero-Diez M, Fraga J, et al. Cutaneous sarcoidosis by interferon therapy in a patient with melanoma. J Eur Acad Dermatol Venereol. 2006;20:1328-1329.
23. Pelletier F, Manzoni P, Jacoulet P, et al. Pulmonary and cutaneous sarcoidosis associated with interferon therapy for melanoma. Cutis. 2007;80:441-445.
24. Suarez-Garcia C, Perez-Gil A, Pereira-Gallardo S, et al. Interferon-induced cutaneous sarcoidosis in melanoma. Melanoma Res. 2009. Epub ahead of print.
25. Wandl UB, Kloke O, Nagel-Hiemke M, et al. Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia. Br J Haematol. 1992;81:516-519.
26. Yavorkovsky LL, Carrum G, Bruce S, et al. Cutaneous sarcoidosis in a patient with Philadelphia-positive chronic myelogenous leukemia treated with interferon-alpha. Am J Hematol. 1998;58:80-81.
27. Kikawada M, Ichinose Y, Kunisawa A, et al. Sarcoidosis induced by interferon therapy for chronic myelogenous leukaemia. Respirology. 1998;3:41-44.
28. Pietropaoli A, Modrak J, Utell M. Interferon-alpha therapy associated with the development of sarcoidosis. Chest. 1999; 116:569-572.
29. Frankova H, Gaja A, Hejlova N. Pulmonary sarcoidosis in a patient with essential thrombocythemia treated with interferon alpha: a short case report. Med Sci Monit. 2000;6:380-382.
30. Mehta CL, Tyler RJ, Cripps DJ. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. J Am Acad Dermatol. 1998;39: 1024-1028.
31. Bobbio-Pallavicini E, Valsecchi C, Tacconi F, et al. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis. 1995;12:140-142.
32. Abdi EA, Nguyen GK, Ludwig RN, et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer. 1987;59:896-900.
33. Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol. 1996;156:4952-4960.
34. Greene CM, Meachery G, Taggart CC, et al. Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J Immunol. 2000;165:4718-4724.
35. Inui N, Chida K, Suda T, et al. TH1/TH2 and TC1/TC2 profiles in peripheral blood and bronchoalveolar lavage fluid cells in pulmonary sarcoidosis. J Allergy Clin Immunol. 2001; 107:337-344.
36. Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol. 2001;166:642-649.
37. Shigehara K, Shijubo N, Ohmichi M, et al. Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoido-sis. Clin Exp Immunol. 2003;132:152-157.
38. Meloni F, Solari N, Cavagna L, et al. Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol. 2009; 27:765-772.